Blockchain Registration Transaction Record

NanoViricides' NV-387 Drug Targets Measles Outbreak as Cases Surge Globally

NanoViricides announces its antiviral drug NV-387 may combat the global measles outbreak, citing safety in Phase I trials and efficacy in animal models as a complement to vaccines.

This news matters because measles, a highly contagious and potentially severe disease, is experiencing a dangerous resurgence in multiple regions, including the U.S., often linked to declining vaccination rates. An effective therapeutic like NV-387 could be a game-changer for public health. It would not only treat infected individuals, reducing suffering and severe complications like pneumonia or encephalitis, but also act as a crucial tool to contain outbreaks by lowering viral transmission. This is especially vital for protecting infants too young for vaccination, immunocompromised individuals, and communities with low vaccine coverage. Successfully developing a broad-spectrum antiviral also has long-term implications, potentially creating a platform technology adaptable for future emerging viral threats, enhancing global pandemic preparedness.